Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 13/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7694912 | 0.72 | PLA2G2A (0.77) | PLA2G2AALDH1A1PLA2G1B | |
| SCHEMBL514915 | 0.71 | SLC6A9 (0.45) | SLC6A9 | |
| SCHEMBL344897 | 0.70 | PLA2G2A (0.84) | PLA2G2AALDH1A1PLA2G1B | |
| SCHEMBL514934 | 0.68 | SLC6A9 (0.49) | SLC6A9 | |
| SCHEMBL514230 | 0.67 | SLC6A9 (0.51) | SLC6A9 | |
| SCHEMBL514917 | 0.66 | HTR3E (0.36) | PLA2G2ASLC6A9 | |
| SCHEMBL514186 | 0.65 | SLC6A9 (0.63) | SLC6A9ALDH1A1MEN1KMT2A | |
| SCHEMBL7965041 | 0.65 | PLA2G2A (0.80) | PLA2G2APLA2G1B | |
| SCHEMBL805632 | 0.65 | MAPT (0.59) | PLA2G2AALDH1A1HTTMEN1KMT2A | |
| SCHEMBL337567 | 0.64 | PLA2G2A (0.61) | PLA2G2APLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029027-A1 | N-[(6-AZA-BICYCLO[3.2.1]OCT-5-YL)-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME | SANOFI (FR) | 2012-02-02 | — | — | US | claimed |
| US-20120029027-A1 | N-[(6-AZA-BICYCLO[3.2.1]OCT-5-YL)-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME | SANOFI (FR) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029027-A1 | N-[(6-AZA-BICYCLO[3.2.1]OCT-5-YL)-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, C1S | PLA2G2A 1026/4885SLC6A9 1683/4885ALDH1A1 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.